Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Repeated dose toxicity: dermal

Currently viewing:

Administrative data

Endpoint:
chronic toxicity: dermal
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: see 'Remark'
Remarks:
The study is comparable to Guideline with acceptable restrictions (only 2 animals per dose; limited parameters in hematology and clinical chemistry; limited documentation of urinalysis; only 3 organs examined in histopathology [liver, kidney, skin]; partly limited documentation [details on test substance, analytical results or animals]).

Data source

Reference
Reference Type:
publication
Title:
Unnamed
Year:
1961

Materials and methods

Test guideline
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 452 (Chronic Toxicity Studies)
GLP compliance:
no
Limit test:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
N,N-dimethylacetamide
EC Number:
204-826-4
EC Name:
N,N-dimethylacetamide
Cas Number:
127-19-5
Molecular formula:
C4H9NO
IUPAC Name:
N,N-dimethylacetamide
Test material form:
liquid
Specific details on test material used for the study:
- Name of test material: dimethylacetamide (DMAC)
No details available.

Test animals

Species:
dog
Strain:
not specified
Sex:
male/female
Details on test animals or test system and environmental conditions:
No details available.

Administration / exposure

Type of coverage:
open
Vehicle:
unchanged (no vehicle)
Details on exposure:
The dose was applied to the shaved skin. Licking was prevented.

REMOVAL OF TEST SUBSTANCE
- Washing: After 5 hours of exposure.
Analytical verification of doses or concentrations:
not specified
Duration of treatment / exposure:
a) 6 months at the two lower dose levels
b) 6 weeks at the two higher dose levels
Frequency of treatment:
Once daily for 5 h (washing); 5 days per week
Doses / concentrationsopen allclose all
Dose / conc.:
0.1 other: mL/kg bw/day
Remarks:
94 mg/kg bw/day
Dose / conc.:
0.32 other: mL/kg bw/day
Remarks:
300 mg/kg bw/day
Dose / conc.:
1 other: mL/kg bw/day
Remarks:
940 mg/kg bw/day
Dose / conc.:
4 other: mL/kg bw/day
Remarks:
3760 mg/kg bw/day
No. of animals per sex per dose:
a) 2 (1 m, 1 f) in the two low dose groups plus control
b) 2 males in the two high dose groups plus control
Control animals:
other: yes, unspecified
Details on study design:
- Post-exposure recovery period in satellite groups: Presumably no post exposure observation period.
Positive control:
No

Examinations

Observations and examinations performed and frequency:
CLINICAL SIGNS:
Clinical signs were recorded (no details).

BODY WEIGHT:
The animals were weighed at weekly intervals.

HEMATOLOGY:
- Time schedule for collection of blood: Initial and after 1, 2, 3, 6 months in a) (no details), weekly in b).
- Parameters examined: Hemoglobin, sedimentation rate, hematocrit, total and differential white blood cell counts.

CLINICAL CHEMISTRY:
- Time schedule for collection of blood: Initial and after 1, 2, 3, 6 months in a) (no details), weekly in b).
- Parameters examined: Blood urea nitrogen (BUN), bromsulphthalein (BSP) dye retention, thymol turbidity, alkaline phosphatase.

URINALYSIS:
Urine analysis was performed but no details given .
Sacrifice and pathology:
GROSS PATHOLOGY:
Gross autopsies were performed upon the animal that died and on the remaining animals sacrificed at termination of the study.

HISTOPATHOLOGY:
Sections of liver, kidney and skin were processed and examined.
Other examinations:
No
Statistics:
No data

Results and discussion

Results of examinations

Clinical signs:
effects observed, treatment-related
Description (incidence and severity):
Anorexia, depression, weakness, ataxia, abdominal tenderness, diarrhea and frank jaundice were present in the dogs on the 4 mL/kg bw/day level just prior to death
Dermal irritation:
effects observed, treatment-related
Description (incidence and severity):
No significant microscopic findings were seen in the skin at 0.1 mL, except for slight thickening and/or inflammatory reaction.
Local effects (ulcer) were observed in 1/2 dogs at 0.32 mL/kg bw/day after 4 month. Administration to this site was stopped, and the ulcer gradually healed over a period of 1 month . The skin of both dogs showed marked scaliness.
Mild to moderate skin irritation at ≥ 1 mL/kg bw/d (at termination of the studies the dogs showed fissuring and thick scales, which resembled eschars).
Mortality:
mortality observed, treatment-related
Description (incidence):
At 4 mL/kg bw/day one dog died after 15 applications and the other was sacrificed moribund at day 16.
At 1 mL/kg bw/day both dogs were sacrificed moribund after 6 weeks of treatment.
Body weight and weight changes:
effects observed, treatment-related
Description (incidence and severity):
Dogs at both high dose levels showed weight loss. At 0.32 mL/kg bw/d there was reduced body weight during the initial exposure period.
Haematological findings:
effects observed, treatment-related
Description (incidence and severity):
At ≥1.0 mL/kg bw/d there was increased hematocrit and hemoglobin, and leukocytosis.
Clinical biochemistry findings:
effects observed, treatment-related
Description (incidence and severity):
At ≥0.32 mL/kg bw/d the activity of alkaline phosphatase was increased. There was altered BSP retention.
Gross pathological findings:
effects observed, treatment-related
Description (incidence and severity):
Pale or yellow liver was noted at necropsy.
Histopathological findings: non-neoplastic:
effects observed, treatment-related
Description (incidence and severity):
Fatty degeneration of the liver was noted at ≥1 mL/kg bw/day (940 mg/kg bw/day); there were no effects noted in the kidneys.

Effect levels

open allclose all
Dose descriptor:
NOAEL
Effect level:
0.1 other: mL/kg bw/day
Sex:
male/female
Basis for effect level:
other: no adverse effects observed at this dose
Remarks on result:
other: 94 mg/kg bw/day
Dose descriptor:
LOAEL
Effect level:
0.32 other: mL/kg bw/day
Sex:
male/female
Basis for effect level:
body weight and weight gain
clinical biochemistry
gross pathology
Remarks on result:
other: 300 mg/kg bw/day

Target system / organ toxicity

Critical effects observed:
not specified

Applicant's summary and conclusion

Conclusions:
In chronic studies toxic effects were detected in dogs after dermal exposure to DMAC at dose levels >=300 mg/kg bw/day. The dermal NOAEL was 94 mg/kg bw/day.
Executive summary:

In a chronic dermal toxicity study comparable to guideline (OECD TG 452) 2 dogs per dose level received 0, 0.10, 0.32, 1.0, or 4.0 mL/kg bw/day corresponding to 0, 94, 300, 940, 3760 mg/kg bw/day to clipped skin. The dermal exposure was conducted openly with washing after 5 h exposure at 5 days per weeks. The exposure period was 6 weeks for the two higher dose levels (lethal effects) and 6 months for the two lower dose levels.

Mortality was observed at the two higher dose levels; dogs died or were sacrificed moribund (after 6 weeks at 1 mL/kg bw/day). At a dose level of 0.32 mL/kg bw/day local effects (ulcer), decrease in body weight, increased activity of alkaline phosphatase, and altered BSP retention were seen. Fatty degeneration of the liver was detected in histopathology at >=1 mL/kg bw/day (940 mg/kg bw/day). No data were available on histopathology of the testes (compare with other repeated dose studies in mouse and rat).

Conclusion: The dermal NOAEL was 94 mg/kg bw/day.